Technical Analysis for VOR - Vor Biopharma Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.79 | 3.87% | 0.03 |
VOR closed up 3.87 percent on Wednesday, November 20, 2024, on 38 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 50 DMA | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 3.87% | |
New Downtrend | Bearish | 3.87% | |
Wide Bands | Range Expansion | 3.87% | |
Down 3 Days in a Row | Weakness | 3.87% | |
Down 4 Days in a Row | Weakness | 3.87% |
Alert | Time |
---|---|
Possible NR7 | about 19 hours ago |
60 Minute Opening Range Breakout | about 20 hours ago |
Rose Above 50 DMA | about 20 hours ago |
Up 5% | about 20 hours ago |
Up 3% | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acute Myeloid Leukemia Tyrosine Kinase Receptors Therapies For Cancer Proteins Haematopoiesis Lintuzumab
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acute Myeloid Leukemia Tyrosine Kinase Receptors Therapies For Cancer Proteins Haematopoiesis Lintuzumab
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.1399 |
52 Week Low | 0.63 |
Average Volume | 553,258 |
200-Day Moving Average | 1.32 |
50-Day Moving Average | 0.79 |
20-Day Moving Average | 0.83 |
10-Day Moving Average | 0.89 |
Average True Range | 0.08 |
RSI (14) | 47.37 |
ADX | 25.12 |
+DI | 23.92 |
-DI | 25.66 |
Chandelier Exit (Long, 3 ATRs) | 0.83 |
Chandelier Exit (Short, 3 ATRs) | 0.90 |
Upper Bollinger Bands | 1.01 |
Lower Bollinger Band | 0.65 |
Percent B (%b) | 0.4 |
BandWidth | 42.97 |
MACD Line | 0.02 |
MACD Signal Line | 0.03 |
MACD Histogram | -0.0114 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.88 | ||||
Resistance 3 (R3) | 0.88 | 0.84 | 0.87 | ||
Resistance 2 (R2) | 0.84 | 0.82 | 0.85 | 0.86 | |
Resistance 1 (R1) | 0.82 | 0.81 | 0.83 | 0.82 | 0.86 |
Pivot Point | 0.79 | 0.79 | 0.79 | 0.79 | 0.79 |
Support 1 (S1) | 0.76 | 0.77 | 0.77 | 0.77 | 0.73 |
Support 2 (S2) | 0.73 | 0.75 | 0.73 | 0.73 | |
Support 3 (S3) | 0.71 | 0.73 | 0.72 | ||
Support 4 (S4) | 0.71 |